Gan & Lee Pharmaceuticals (SHA: 603087), a Chinese pharmaceutical company, has announced that it has received marketing approval for its insulin glargine pre-filled pen in Mexico. This marks the company’s first marketing authorization as a holder (MAH) in the Mexican market.
Insulin glargine, a long-acting insulin analogue that requires daily administration, is known for its prolonged duration of action, lack of peak blood drug concentration, and stable reduction of blood sugar levels in patients, offering a good therapeutic effect and safety profile. With this approval, Gan & Lee Pharma’s product is set to directly compete with Sanofi’s originator product Lantus in Mexico.
Gan & Lee Pharmaceuticals boasts a portfolio of 6 insulins, including 5 insulin analogues, which have been approved for marketing across 21 countries and regions worldwide.- Flcube.com
